ASA Dry Powder Composition With Micronized MgST Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Magnesium stearate (MgST) is known to catalyze acid-based hydrolysis, making it incompatible with active pharmaceutical ingredients (APIs) susceptible to acid-based degradation, such as acetylsalicylic acid (ASA), and existing formulations of ASA/MgST show instability under various conditions.
Innovation Solution
Development of stable dry powder compositions comprising ASA and MgST with specific particle characteristics, including MMAD, FPF, GSD, and ED, which maintain high stability and dispersibility even under harsh conditions, allowing for pulmonary delivery via dry powder inhalers (DPI) or metered dose inhalers (MDI).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If magnesium stearate is used as an excipient in ASA formulations, then flowability and compressibility are improved, but chemical stability deteriorates due to acid-based hydrolysis catalysis
Solution Approach 1:
The patent changes the physical parameters of magnesium stearate by micronizing it to achieve a particle size distribution with D10 of 1-3 μm, D50 of 3-6 μm, and D90 of 6-12 μm. This parameter change in particle size improves the compatibility between MgST and ASA, allowing the formulation to maintain both manufacturability and chemical stability for up to 12 months under various storage conditions.
Solution Approach 2:
The patent creates a composite dry powder formulation consisting of micronized magnesium stearate and acetylsalicylic acid with specific particle size distributions. This composite material approach allows the combination of MgST's beneficial properties (flowability, compressibility) with improved chemical stability through the controlled particle size interaction between the excipient and API.
2Ease of manufacture
If conventional ASA/MgST formulations are prepared, then manufacturing is simplified, but particle stability and chemical integrity deteriorate under varying conditions
Solution Approach 1:
The patent introduces specific particle size distribution parameters (D10: 1-3 μm, D50: 3-6 μm, D90: 6-12 μm) as control variables in the formulation. This parameter-based approach maintains manufacturing simplicity while significantly improving particle stability and chemical integrity under varying storage conditions, including temperature and humidity variations.
Solution Approach 2:
The patent replaces conventional mixing and size reduction methods with a micronization process that produces a controlled particle size distribution. This substitution of the mechanical processing system achieves both manufacturing feasibility and enhanced particle stability without requiring complex formulation approaches.
3Speed
If ASA is formulated with MgST for pulmonary delivery, then rapid onset of action is achieved, but drug degradation increases due to hydrolysis catalysis
Solution Approach 1:
The patent changes the particle size parameter of magnesium stearate to a micronized range (D10: 1-3 μm, D50: 3-6 μm, D90: 6-12 μm), which reduces drug degradation from hydrolysis catalysis while preserving the rapid onset of action required for pulmonary delivery. This parameter optimization allows the formulation to maintain both therapeutic efficacy and chemical stability.
Solution Approach 2:
The patent converts the potentially harmful interaction between MgST and ASA into a beneficial outcome by controlling the particle size of MgST. The micronized form of MgST, rather than catalyzing hydrolysis, actually stabilizes the ASA formulation, transforming the harmful catalytic effect into a beneficial stabilizing effect while maintaining rapid pulmonary delivery.
Data Source
AI summary
A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 μm to about 5 μm. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.